Clinical Trials Browser

Terminated × bivatuzumab mertansine × Breast × Clear all

NCT02254031 2023-10-24

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms